# Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-mh-24-151-single-source-accelerating-medicines-partnership/  
Official notice: https://www.grants.gov/search-results-detail/349227

> National Institutes of Health offered grants to colleges and universities. Applications closed on October 17, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-MH-24-151 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | October 17, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.242 |

## Who can apply

- Public and State controlled institutions of higher education

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see NOFO for eligibility details

## What the grant funds

The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clinical outcome measures) previously assessed in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) project. The CTDPACC will support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial utilizing a Phase 2 ready compound or compounds.

## Questions people ask

### Is RFA-MH-24-151 still open?

No. It closed on October 17, 2023.

### Who can apply for Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)?

Closed October 17, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-MH-24-151?

NIH RePORTER lists 1 project funded under RFA-MH-24-151 in fiscal 2024 to 2026, at 1 institution.

### Who has won Mental Health Research Grants grants before?

The largest recipients over five fiscal years were Yale Univ, University of Pittsburgh - of the Commonwealth System of Higher Education, University of California, Los Angeles. The program made 6,785 awards worth $8.8 billion in that time.